About Plasma serine protease inhibitor
Plasma serine protease inhibitor (SERPINA5) is a protein
from Homo sapiens identified by UniProt accession
P05154, 406 residues long.
MolForge cross-references it against 0 known binders and
219 disease associations.
Target properties
| Protein name | Plasma serine protease inhibitor |
| UniProt accession | P05154 |
| Gene | SERPINA5 |
| Organism | Homo sapiens |
| Length | 406 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (219)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.47
- sex hormone-binding globulin measurement · score 0.45
- serum albumin measurement · score 0.43
- total blood protein measurement · score 0.36
- calcium measurement · score 0.30
- CD27 antigen measurement · score 0.28
- kallistatin measurement · score 0.27
- lung adenocarcinoma · score 0.25
- glioblastoma multiforme · score 0.24
- cutaneous melanoma · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P05154-F1 | alphafold | PREDICTED | 85.14 | — |
Amino-acid sequence (406 residues)
MQLFLLLCLV LLSPQGASLH RHHPREMKKR VEDLHVGATV APSSRRDFTF DLYRALASAA PSQSIFFSPV SISMSLAMLS LGAGSSTKMQ ILEGLGLNLQ KSSEKELHRG FQQLLQELNQ PRDGFQLSLG NALFTDLVVD LQDTFVSAMK TLYLADTFPT NFRDSAGAMK QINDYVAKQT KGKIVDLLKN LDSNAVVIMV NYIFFKAKWE TSFNHKGTQE QDFYVTSETV VRVPMMSRED QYHYLLDRNL SCRVVGVPYQ GNATALFILP SEGKMQQVEN GLSEKTLRKW LKMFKKRQLE LYLPKFSIEG SYQLEKVLPS LGISNVFTSH ADLSGISNHS NIQVSEMVHK AVVEVDESGT RAAAATGTIF TFRSARLNSQ RLVFNRPFLM FIVDNNILFL GKVNRP
Explore Plasma serine protease inhibitor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets